



Boehringer
Ingelheim



evotec



Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance

France and Germany July 6, 2022 - **Boehringer Ingelheim**, a leading research-driven biopharmaceutical company, the life science company **Evotec SE** (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and **bioMérieux**, a world leader in *in vitro* diagnostics, announced today that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR).

The resulting company, Aurobac Therapeutics SAS, will combine the best-of-best capabilities of the three founding companies towards developing a new precision medicine approach, from diagnosis to cure. The aspiration is to succeed in the fight against AMR, which is a major public health threat. Having routine surgery such as caesarean sections or hip replacements may become life threatening, and complications from common diseases such as diabetes and injuries or cuts will become harder to manage because of AMR.

“The rise of antibiotic-resistant infections – also called Antimicrobial Resistance, or AMR – is indeed a looming global crisis,” said Michel Pairet, Head of **Boehringer Ingelheim’s** Innovation unit and Member of the Board of Managing Directors. *“Antibiotic resistance kills about [1.27 million people globally every year](#)¹ and it has been estimated that by 2050, as many as [10 million worldwide deaths could result from AMR](#)², making it potentially deadlier than cancer.”*

Werner Lanthaler, CEO of Evotec added: *“The grim prospect of a post-antibiotic era has many causes but only one solution: The development of new, targeted, and effective antimicrobial therapies. We are excited to launch Aurobac together with our partners at **Boehringer Ingelheim** and **bioMérieux**, to combine our complementary strengths. By leveraging Evotec’s multimodality approach to infectious diseases, we are confident that Aurobac will be able to generate much-needed progress to tackle the global challenge of AMR”.*

“bioMérieux has a strong expertise in Antimicrobial Resistance. We supply the most comprehensive integrated diagnostic solutions to support an appropriate use of antibiotics (Antimicrobial Stewardship),” said Alexandre Mérieux, **bioMérieux** Chairman and CEO. *“Our role within the joint venture is to develop and commercialize diagnostic tests, including Companion Diagnostics, which deliver rapid, reliable and actionable results. This participation in Aurobac is perfectly aligned with **bioMérieux’s** full commitment to sustain antibiotic efficacy for future generations”.*

Aurobac will work to shift the strategy related to antibiotic treatment regimens, which at the moment leans heavily on empirical approaches using broad-spectrum and unfocused medicines. The goal is to turn this into a precision approach, using new highly effective and targeted modalities, combined with rapid and actionable diagnostics to quickly identify pathogens and their resistance patterns, and supported by new economic models.

PRESS RELEASE

Funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each, the 40 million EUR joint venture, which has its headquarters in Lyon (France), combines the world leading expertise of Evotec, one of the most active research companies in infectious diseases, with bioMérieux' market-leading expertise in infectious disease diagnostics and with Boehringer Ingelheim's broad drug discovery and significant clinical development capabilities.

Three partners committed to combat AMR

Boehringer Ingelheim's participation in Aurobac is part of a wider so-called pandemic preparedness initiative, which includes a 50 million EUR investment in the AMR action fund by Boehringer Ingelheim. Boehringer Ingelheim Venture Fund has committed to invest up to 12 million EUR in AMR infection companies.

bioMérieux has over 55 years of diagnostics expertise with more than 75% of its research and development budget focused on antimicrobial resistance. Moreover, 80% of its turnover is related to the fight against AMR through a complete diagnostic solution facilitating antibiotic therapy decision-making, including antibiotic initiation, optimization, and discontinuation.

Evotec has built a world-leading platform to tackle infectious diseases. With a more than 200-strong anti-infective discovery team, the company has proven experience on multiple agent classes. On top of the company's own pre-competitive pandemic preparedness and rapid response technology platform ("PRROTECT"), Evotec leverages its infectious disease capabilities with many industry, academic and non-profit partners and is active in a variety of networks such as the AMR Accelerator that is part of the EU's Innovative Medicines Initiative ("IMI").

¹[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(21\)02724-0/fulltext#seccestitle10](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02724-0/fulltext#seccestitle10)

²https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf

ABOUT BOEHRINGER INGELHEIM

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 52,000 employees serve over 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at www.boehringer-ingelheim.com

ABOUT EVOTEC SE

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,200 highly qualified people. The Company's 15 sites offer highly synergistic technologies and services and operate as complementary

clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter [@Evotec](https://twitter.com/Evotec) and [LinkedIn](https://www.linkedin.com/company/evotec).

ABOUT BIOMÉRIEUX

Pioneering Diagnostics

A world leader in the field of *in vitro* diagnostics since 1963, bioMérieux is present in 44 countries and serves more than 160 countries with the support of a large network of distributors. In 2021, revenues reached €3.4 billion, with over 90% of sales outside of France.

bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

www.biomerieux.com.



bioMérieux is listed on the Euronext Paris stock market.

Symbol: BIM – ISIN Code: FR0013280286

Reuters: BIOX.PA/Bloomberg: BIM.FP

CONTACTS

Investor Relations

bioMérieux

Franck Admant

Tel.: +33 (0)4 78 87 20 00

investor.relations@biomerieux.com

Media Relations

Boehringer Ingelheim

Harro Ten Wolde

Tel.: +49 (6132) 77-181352

harro.ten_wolde@boehringer-ingelheim.com

bioMérieux

Romain Duchez

Tel.: +33 (0)4 78 87 21 99

romain.duchez@biomerieux.com